OOIR: Observatory of International Research

Papers

(The H4-Index of Blood Reviews is 30. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Interplay between platelets and coagulation	188
Targeting MCL-1 in hematologic malignancies: Rationale and progress	140
Coagulation and anticoagulation in COVID-19	140
Coagulation dysfunction in COVID-19: The interplay between inflammation, viral infection and the coagulation system	128
Weathering the COVID-19 storm: Lessons from hematologic cytokine syndromes	114
The impact of ABO blood group on COVID-19 infection risk and mortality: A systematic review and meta-analysis	104
Platelet activation and prothrombotic mediators at the nexus of inflammation and atherosclerosis: Potential role of antiplatelet agents	98
Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions	82
A review of FLT3 inhibitors in acute myeloid leukemia	77
Myeloid sarcoma, chloroma, or extramedullary acute myeloid leukemia tumor: A tale of misnomers, controversy and the unresolved	72
Coagulopathy and sepsis: Pathophysiology, clinical manifestations and treatment	71
The looming storm: Blood and cytokines in COVID-19	68
When hematologic malignancies meet COVID-19 in the United States: Infections, death and disparities	59
COVID-19 breakthrough infections, hospitalizations and mortality in fully vaccinated patients with hematologic malignancies: A clarion call for maintaining mitigation and ramping-up research	56
Understanding terminal erythropoiesis: An update on chromatin condensation, enucleation, and reticulocyte maturation	53
Graft-versus-host disease prophylaxis: Pathophysiology-based review on current approaches and future directions	53
Current state and next-generation CAR-T cells in multiple myeloma	53
Illness and prognostic understanding in patients with hematologic malignancies	48
Hematopoietic versus leukemic stem cell quiescence: Challenges and therapeutic opportunities	46
Recent progress in and challenges in cellular therapy using NK cells for hematological malignancies	43
Inherited thrombocytopenias: an updated guide for clinicians	43
Current and emerging strategies for management of myelodysplastic syndromes	40
Discussing investigational AAV gene therapy with hemophilia patients: A guide	40
Second primary malignancies in multiple myeloma: A review	38
Complement activation in COVID-19 and targeted therapeutic options: A scoping review	36

IKZF1 alterations in acute lymphoblastic leukemia: The good, the bad and the ugly	35
Clinical outcomes of COVID-19 in patients with sickle cell disease and sickle cell trait: A critical appraisal of the literature	34
Optimising prophylaxis in haemophilia A: The ups and downs of treatment	34
Allogeneic hematopoietic stem cell transplantation in aplastic anemia: current indications and transplant strategies	33
Targeting the gut microbiome: An emerging trend in hematopoietic stem cell transplantation	31